Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

Staphylococcus aureus

  • <em>De Novo</em> Resistance to Arg<sub>10</sub>-Teixobactin Occurs Slowly and Is Costly
    Mechanisms of Resistance
    De Novo Resistance to Arg10-Teixobactin Occurs Slowly and Is Costly

    Bacterial pathogens are rapidly evolving resistance to all clinically available antibiotics. One part of the solution to this complex issue is to better understand the resistance mechanisms to new and existing antibiotics. Here, we focus on two antibiotics. Teixobactin is a recently discovered promising antibiotic that is claimed to “kill pathogens without detectable resistance” (L. L. Ling, T. Schneider, A. J. Peoples, A. L. Spoering,...

    Daniel G. Lloyd, Benjamin J. Schofield, Matthew R. Goddard, Edward J. Taylor
  • A Population Pharmacokinetic Analysis of Continuous Infusion of Cloxacillin during <em>Staphylococcus aureus</em> Bone and Joint Infections
    Clinical Therapeutics
    A Population Pharmacokinetic Analysis of Continuous Infusion of Cloxacillin during Staphylococcus aureus Bone and Joint Infections

    Intravenous administration of antibiotics is recommended during the early phase of methicillin-susceptible S. aureus (MSSA) bone and joint infection (BJI). We sought to compare the plasma concentrations of cloxacillin administered alternately by continuous and intermittent infusion (CI and ItI) in patients with MSSA BJI. In this prospective crossover trial, patients...

    Johan Courjon, Margaux Garzaro, Pierre-Marie Roger, Raymond Ruimy, Thibaud Lavrut, Mikaël Chelli, Jean-Luc Raynier, David Chirio, Elisa Demonchy, Laura Cabane, François Jehl, Christophe Trojani, Antoine Grillon, Sylvain Goutelle
  • <em>In Vitro</em> Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
    Epidemiology and Surveillance
    In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

    Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates (n = 1,211). Contezolid demonstrated potent activity against Staphylococcus aureus (MIC50/90, 0.5/1 mg/liter), coagulase-negative Staphylococcus...

    Cecilia G. Carvalhaes, Leonard R. Duncan, Wen Wang, Helio S. Sader
  • Comparative <em>In Vitro</em> Activities of Ceftaroline and Tedizolid against Clinical Strains of <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> and <em>Enterococcus</em>: Results from the China Antimicrobial Surveillance Network (CHINET) in 2018
    Susceptibility
    Comparative In Vitro Activities of Ceftaroline and Tedizolid against Clinical Strains of Staphylococcus aureus and Enterococcus: Results from the China Antimicrobial Surveillance Network (CHINET) in 2018

    The in vitro activities of ceftaroline and tedizolid were compared against Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium clinical isolates collected from the China Antimicrobial Surveillance...

    Yan Guo, Yang Yang, Yonggui Zheng, Shi Wu, Dandan Yin, Demei Zhu, Fupin Hu
    and on behalf of China Antimicrobial Surveillance Network (CHINET) Study Group
  • Open Access
    Povidone Iodine: Properties, Mechanisms of Action, and Role in Infection Control and <em>Staphylococcus aureus</em> Decolonization
    Minireview
    Povidone Iodine: Properties, Mechanisms of Action, and Role in Infection Control and Staphylococcus aureus Decolonization

    Nasal decolonization is an integral part of the strategies used to control and prevent the spread of methicillin-resistant Staphylococcus aureus (MRSA) infections. The two most commonly used agents for decolonization are intranasal mupirocin 2% ointment and chlorhexidine wash, but the increasing emergence of resistance and treatment failure has underscored the need...

    Didier Lepelletier, Jean Yves Maillard, Bruno Pozzetto, Anne Simon
  • Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> Bacteremia
    Minireview
    Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia

    Methicillin-resistant Staphylococcus aureus (MRSA) has grown to become a major burden on health care systems. The cumulation of limited therapeutic options and worsened patient outcomes with persistent MRSA bacteremia has driven research in optimizing its initial management. The guidelines published by the Infectious Diseases Society of America currently recommend...

    H Andrew Wilsey, Donna R. Burgess, David S. Burgess
  • Free
    Early Oral Antibiotic Switch for <em>Staphylococcus aureus</em> Bacteremia: Many Are Called, but Few Are Chosen
    Editor's Pick Commentary
    Early Oral Antibiotic Switch for Staphylococcus aureus Bacteremia: Many Are Called, but Few Are Chosen

    Staphylococcus aureus bacteremia (SAB) is a complicated, high-risk disease. For selected low-risk SAB, the role of oral antibiotic stepdown therapy is unknown. Bupha-Intr et al. report a retrospective cohort of low-risk SAB patients who did well with a short duration of intravenous antibiotics, followed by an additional ∼10 days of oral antibiotics, primarily using...

    Thomas L. Holland
  • Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span>
    Experimental Therapeutics
    Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus

    Comparative time-kill experiments with Staphylococcus aureus bacteriophage (phage) Sb-1 alone and phage-antibiotic combinations (PACs) against two methicillin-resistant S. aureus (MRSA) strains have shown synergy with both daptomycin-phage and vancomycin-phage combinations. PACs prevented...

    Razieh Kebriaei, Katherine Lev, Taylor Morrisette, Kyle C. Stamper, Jacinda C. Abdul-Mutakabbir, Susan M. Lehman, Sandra Morales, Michael J. Rybak
  • Methicillin-Resistant <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> (MRSA) Nasal Screening: Clinical Use for Excluding Diabetic Foot Infection with MRSA
    Letter to the Editor
    Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening: Clinical Use for Excluding Diabetic Foot Infection with MRSA
    Maroun M. Sfeir
  • <em>In Vitro</em> and <em>In Vivo</em> Antibiotic Capacity of Two Host Defense Peptides
    Mechanisms of Action: Physiological Effects
    In Vitro and In Vivo Antibiotic Capacity of Two Host Defense Peptides

    Two nonamidated host defense peptides named Pin2[G] and FA1 were evaluated against three types of pathogenic bacteria: two (Staphylococcus aureus UPD13 and Pseudomonas aeruginosa UPD3) isolated from diabetic foot ulcer patients, and another (...

    Iván Arenas, Marco Antonio Ibarra, Felix L. Santana, Elba Villegas, Robert E. W. Hancock, Gerardo Corzo

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 72
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596